Angion Biomedica Corp. Common Stock (ANGN)

Etorro trading 970x250

About Angion Biomedica Corp. Common Stock

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company’s lead product candidate is ANG-3777, a hepatocyte growth factor mimetic for acute kidney injury, acute lung injury, acute respiratory distress syndrome, central nervous system injuries, and heart injuries. It also develops products, such as ANG-3070 tyrosine kinase inhibitor and rho kinase 2 inhibitors for fibrotic diseases; and CYP11B2, an aldosterone synthase inhibitor for aldosterone-related fibrotic diseases. The company was incorporated in 1998 and is based in Uniondale, New York with additional offices in San Francisco, California and Newton, Massachusetts. Address: 51 Charles Lindbergh Boulevard, Uniondale, NY, United States, 11553

Angion Biomedica Corp. Common Stock News and around…

Latest news about Angion Biomedica Corp. Common Stock (ANGN) common stock and company :

Mid-Afternoon Market Update: Nasdaq Surges Over 100 Points; Cortexyme Shares Plunge
27 Oct, 2021 FinancialContent

Toward the end of trading Wednesday, the Dow traded down 0.23% to 35,674.01 while the NASDAQ rose 0.81% to 15,358.79. The S&P also ...

Mid-Day Market Update: Dow Falls Over 100 Points; Silicon Laboratories Shares Spike Higher
27 Oct, 2021 FinancialContent

Midway through trading Wednesday, the Dow traded down 0.30% to 35,648.39 while the NASDAQ rose 0.32% to 15,283.97. The S&P also ...

Why Did Angion Biomedica's Shares tumble Premarket Today?
27 Oct, 2021 FinancialContent

After flopping a test in COVID-19 earlier this year,Angion Biomedica Corp's(NASDAQ: ANGN) lead candidate drug has hit ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
27 Oct, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! We're halfway through the week and still starting it with a breakdown of the biggest pre-market stock movers. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

28 Stocks Moving in Wednesday's Pre-Market Session
27 Oct, 2021 FinancialContent

Gainers China XD Plastics Company Limited (NASDAQ: CXDC) rose 139% to $1.40 in pre-market trading after jumping around 30% on ...

Vifor Pharma and Angion report topline results from phase-III registration trial of ANG-3777 in kidney transplant patients at risk for delayed graft function
27 Oct, 2021 FinancialContent

Regulatory News:

Angion and Vifor Pharma Report Topline Results from Phase 3 Trial of ANG-3777 in Kidney Transplant Patients at Risk for Delayed Graft Function
26 Oct, 2021 Yahoo! Finance

Angion to host a conference call at 4:30 p.m. EDTUNIONDALE, N.Y. and ST. GALLEN, Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced the Phase 3 trial of Angion’s ANG-3777 did not demonstrate a statistically significant difference from placebo on the primary endpoint (eGFR at 12 months) in the population of deceased donor kidney transplant patients who were at risk for developing delayed graft function (DGF). ANG-3777 showed a mode

10 Healthcare Stocks to Buy According to Peter S. Park’s Park West Asset Management
21 Oct, 2021 Yahoo! Finance

In this article, we discuss the 10 healthcare stocks to buy according to Peter S. Park’s Park West Asset Management based on Q2 holdings of the fund. If you want to skip our detailed analysis of Park’s history, investment philosophy, and hedge fund performance, go directly to the 5 Healthcare Stocks to Buy According to […]

Angion to Present Multiple Posters at Kidney Week 2021
18 Oct, 2021 Yahoo! Finance

UNIONDALE, N.Y., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced it will be presenting four posters at the American Society of Nephrology’s Kidney Week 2021 virtual meeting to be held November 4-7, 2021. All Angion’s posters will be available on the Kidney Week 2021 we

Angion Biomedica Corp. (NASDAQ:ANGN) Shares Could Be 37% Below Their Intrinsic Value Estimate
18 Oct, 2021 Yahoo! Finance

Does the October share price for Angion Biomedica Corp. ( NASDAQ:ANGN ) reflect what it's really worth? Today, we will...

Look Under The Hood: IWO Has 28% Upside
14 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Russell 2000 Growth ETF (IWO), we found that the implied analyst target price for the ETF based upon its underlying holdings is $381.25 per unit.

10 Pharmaceutical Stocks to Buy According to Timothy Lynch’s Stonepine Capital
14 Oct, 2021 Yahoo! Finance

In this article, we take a look at the 10 pharmaceutical stocks to buy according to Timothy Lynch’s Stonepine Capital. If you want to skip our detailed analysis of Stonepine Capital’s history, investment philosophy, and hedge fund preference, go directly to 5 Pharmaceutical Stocks to Buy According to Timothy Lynch’s Stonepine Capital. Timothy Lynch is […]

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
08 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
07 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
06 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Peek Under The Hood: IWO Has 23% Upside
10 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Russell 2000 Growth ETF (IWO), we found that the implied analyst target price for the ETF based upon its underlying holdings is $374.93 per unit.

Angion Hosting Research & Development Day on ANG-3070 for the Treatment of Lung and Kidney Fibrosis
08 Sep, 2021 FinancialContent
Angion to Participate in Upcoming September Investment Conferences
02 Sep, 2021 FinancialContent
We're Hopeful That Angion Biomedica (NASDAQ:ANGN) Will Use Its Cash Wisely
19 Aug, 2021 Yahoo! Finance

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
19 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
18 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
17 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

77 Biggest Movers From Yesterday
13 Aug, 2021 FinancialContent

Gainers Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) shares surged 65.4% to close at $2.10 on Thursday after the company ...

Angion Provides Corporate Update and Reports Second Quarter 2021 Financial Results
12 Aug, 2021 FinancialContent
85 Biggest Movers From Yesterday
11 Aug, 2021 FinancialContent

Gainers Fulcrum Therapeutics, Inc. (NASDAQ: FULC) jumped 125.3% to close at $18.77 on Tuesday after the company announced positive ...

Analysts Predict 38% Gains Ahead For IWC
09 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Micro-Cap ETF (IWC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $201.98 per unit.

Angion Biomedica Shares Moving Higher On Encouraging Results From Early Stage Trial Of Fibrotic Disease Candidate
03 Aug, 2021 FinancialContent

Angion Biomedica Corp(NASDAQ: ANGN)has announced positive resultsfrom its Phase 1 study in healthy volunteers for ...

The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
03 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Angion Reports Positive Results from Phase 1 Healthy Volunteer Study for ANG-3070 and FDA Authorization to Initiate Phase 2 Trial in 2021
03 Aug, 2021 FinancialContent
The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
16 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Angion Biomedica Corp. Common Stock (ANGN) is a NASDAQ Common Stock listed in , ,

970x250